Investigate Low Doses of Direct Oral Anticoagulants
June 2017
More patients will be admitted on LOW-dose direct oral anticoagulants (DOACs) to prevent recurrent venous thromboembolism (VTE).
Most patients who have a VTE due to a short-term risk...such as surgery or minor trauma...will use warfarin or a DOAC (apixaban, etc) for just 3 months.
Long-term anticoagulation is needed for most patients at high risk of recurrence...such as those with active cancer or a clotting disorder.
Get concise advice on drug therapy, plus unlimited access to CE
Hospital Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote